Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Single-Center Experience with Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Comparable Response Rates and Manageable Toxicity

Veit Buecklein, MD, Viktoria Blumenberg, MD, Josephine Ackermann, Christian Schmidt, MD, Kai Rejeski, MD, Niklas Mueller, MD, Anna Reischer, MD, Louisa von Baumgarten, MD, Florian Schoeberl, MD, Andreas Humpe, MD, Michael von Bergwelt, MD PhD, Marion Subklewe, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-142932

Published: 2020

Journal Articles

Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells

Viktoria Blumenberg, MD, Maria-Luisa Schubert, MD, Eli Zamir, Sabine Schmidt, Roman Rohrbach, Philipp Waldhoff, Daria Bozic, Hendrik Pock, MD, Eran Elinav, Christian Schmidt, MD, Veit Buecklein, MD, Carsten Müller-Tidow, MD, Peter Dreger, MD, Michael von Bergwelt, MD PhD, Michael Schmitt, MD, Marion Subklewe, MD, Christoph Stein-Thöringer, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-141210

Published: 2020

Journal Articles

Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTE® Construct Stimulation in Vitro

Nora Zieger, Alyssa Nicholls, Jan Wulf, Gerulf Hänel, Maryam Kazerani Pasikhani, Veit Buecklein, MD, Bettina Brauchle, Anetta Marcinek, Daniel Nixdorf, Lisa Rohrbacher, Michaela Scheurer, Roman Kischel, MD, Karsten Spiekermann, MD, Oliver Weigert, MD, Sebastian Theurich, MD, Michael von Bergwelt, MD PhD, Marion Subklewe, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137421

Published: 2020

Journal Articles

Treosulfan- Versus Melphalan-Based Reduced Intensity Conditioning in Sequential HLA-Haploidentical Transplantation Using Ptcy As GvHD Prophylaxis in High-Risk MDS /AML of the Elderly: A Matched-Pair Analysis

Alessia Fraccaroli, MD, Sarah Haebe, MD, Heidrun Drolle, Elena Stauffer, Elena.Stauffer@MDuni-muenchen.de, Veit Buecklein, MD, Dusan Prevalsek, Michael von Bergwelt, MD PhD, Johanna Tischer

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-142708

Published: 2020

Journal Articles

Identification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies

Kai Rejeski, MD, Carolina Berger, Liv Jentzsch, Semjon Willier, MD, Viktoria Blumenberg, MD, Veit Buecklein, MD, Christoph Faul, MD, Christian Schmidt, MD, Michael von Bergwelt, MD PhD, Tobias Feuchtinger, MD, Wolfgang Bethge, MD, Francis A. Ayuk, Marion Subklewe, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-141833

Published: 2020

Journal Articles

The Ratio of Costimulatory Vs Coinhibitory Molecules on AML Cells Determines the CD33-BiTE ® Mediated T-Cell Response

Anetta Marcinek, MSc, Bettina Brauchle, MSc, Dragica Udiljak, Roman Kischel, MD, Peter Kufer, MD, Karsten Spiekermann, MD, Michael von Bergwelt, MD, Felix S. Lichtenegger, MD, Marion Subklewe, MD

Blood (2018) 132 (Supplement 1): 1349.

https://doi.org/10.1182/blood-2018-99-116297

Published: 2018

Journal Articles

Favorable Outcome of Sequential HLA-Haploidentical Transplantation Using Ptcy As GvHD Prophylaxis in High Risk AML and MDS of the Elderly

Alessia Fraccaroli, MD, Dusan Prevalsek, Sarah Elena Häbe, Veit Bücklein, MD, Christoph Schulz, MD, Heidrun Drolle, Susanne Fritsch, Georg Ledderose, Michael von Bergwelt, MD, Wolfgang Hiddemann, PhD, Johanna Tischer

Blood (2018) 132 (Supplement 1): 3458.

https://doi.org/10.1182/blood-2018-99-119103

Published: 2018

Journal Articles

NPM1 Variant Allele Frequency and Outcomes in AML

Blood (2018) 132 (Supplement 1): 1486.

https://doi.org/10.1182/blood-2018-99-112549

Published: 2018

NARROW

Single-Center Experience with Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Comparable Response Rates and Manageable Toxicity

Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells

Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTE® Construct Stimulation in Vitro

Treosulfan- Versus Melphalan-Based Reduced Intensity Conditioning in Sequential HLA-Haploidentical Transplantation Using Ptcy As GvHD Prophylaxis in High-Risk MDS /AML of the Elderly: A Matched-Pair Analysis

Identification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies

The Ratio of Costimulatory Vs Coinhibitory Molecules on AML Cells Determines the CD33-BiTE ® Mediated T-Cell Response

Favorable Outcome of Sequential HLA-Haploidentical Transplantation Using Ptcy As GvHD Prophylaxis in High Risk AML and MDS of the Elderly

NPM1 Variant Allele Frequency and Outcomes in AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only